Animal StudyPubMed ID: 15949023·2005

Intranasal Semax Pharmacokinetics: Brain Penetration, CSF Levels, and Regional Distribution

Ashmarin IP, Kamayev YA, Lyapina LA, et al.

Journal of Pharmaceutical and Biomedical Analysis, 2005

Key finding

Intranasal semax reached CSF within 10 minutes; peak CSF levels at 30 minutes; preferential accumulation in hippocampus (3-fold higher than cortex).

Summary

Pharmacokinetic study of intranasal semax showing olfactory bulb-to-brain transit and regional accumulation in hippocampus and cortex.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaxL3

A synthetic peptide analog of ACTH(4-10) approved in Russia as a nootropic, studied for cognitive enhancement and neuroprotection.

More research on Semax

Semax Restores Behavioral Performance and Spatial Memory in Alzheimer Disease Model Mice

Neurobiology of Aging · 2011 · Animal Study

Semax Reduces Brain Inflammation and Microglial Activation After Stroke

Journal of Neuroimmunology · 2010 · Animal Study

Semax Effects on BDNF, NGF, and GDNF: Neurotrophic Factor Signaling in Recovery From Neuronal Injury

Journal of Molecular Neuroscience · 2010 · Animal Study

Semax Improves Optic Nerve Function and Visual Acuity in Patients with Optic Neuropathy

Journal of the Neurological Sciences · 2009 · Human RCT

Semax Effects on Immune Function: Enhanced T-Cell Proliferation and Altered Cytokine Profile

International Immunology · 2009 · Human Pilot